New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.00b market cap, or US$31.8m). 공고 • Mar 23
MegaPro Biomedical Co., Ltd, Annual General Meeting, Jun 23, 2026 MegaPro Biomedical Co., Ltd, Annual General Meeting, Jun 23, 2026, at 10:00 Taipei Standard Time. Location: 10 floor no,350, sung chiang rd., jhongshan district, taipei city Taiwan New Risk • Feb 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (NT$763.7m market cap, or US$24.2m). New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (NT$650.4m market cap, or US$19.7m). 공고 • Apr 01
MegaPro Biomedical Co., Ltd, Annual General Meeting, Jun 20, 2025 MegaPro Biomedical Co., Ltd, Annual General Meeting, Jun 20, 2025, at 10:00 Taipei Standard Time. Location: 10 floor no,350, sung chiang rd., jhongshan district, taipei city Taiwan New Risk • Apr 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (NT$1.77b market cap, or US$55.3m). 공고 • Mar 16
MegaPro Biomedical Co., Ltd, Annual General Meeting, May 31, 2024 MegaPro Biomedical Co., Ltd, Annual General Meeting, May 31, 2024. New Risk • Jan 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (NT$1.41b market cap, or US$45.1m). 공고 • Jul 26
Megapro Biomedical Co., Ltd Successfully Completes the Biological Evaluations of Iop as Vaccine Adjuvant T Cell Mediated Immunity Is Substantially Enhanced, Improving the Efficacy of Vaccines MegaPro Biomedical Co. Ltd. has successfully completed the biological evaluations of their iron oxide nanoparticle platform (hereinafter referred to as IOP) as vaccine adjuvant. Compared with commercially available adjuvants, the IOP can stimulate higher T cell mediated immunity, foreshadowing that the IOP is expected to become a new generation of vaccine adjuvant. MegaPro states that in the process of vaccine development, in addition to the requirement of selecting the appropriate antigen, the adjuvant also plays a very important role. Adjuvants are mainly used to help induce, prolong, and enhance specific immune responses to target antigens. Using the appropriate adjuvant can effectively improve the efficacy of vaccines. In recent years, vaccine adjuvants that can enhance T cell mediated immunity attracts more and more attention. According to the latest test results, the IOP developed as a vaccine adjuvant can boost higher T cell mediated immunity than commercially available adjuvants (such as polyI:C or sapronin). IOP has the potential to replace or combine with these commercial products and become the new generation of vaccine adjuvants. MegaPro states that in addition to being phagocytosed by macrophages, IOPs can also be efficiently uptaken by another type of antigen-presenting cells (APC) called dendritic cells. After foreign matter enters the body, macrophages and dendritic cells as the first-line of APC in the human body, especially when dendritic cells are activated, they would interact with T lymphocytes and B lymphocytes, awakening T lymphocytes and triggering a strong immune response. According to the most recent results of cell experiments, IOP can not only be uptaken by dendritic cells, but also promote the maturation and activation of these dendritic cells, greatly increasing the biochemical indexes of CD80, CD86, CD205, CD40, MHC II, revealing that the activation efficiency of dendritic cells to be increased to 70-80%. In terms of cytokines induction, IOP can induce dendritic cells to produce high levels of IL-12, IL-9, MCP-1, which indicated the high potential for directing the type 1 helper T cell (Th1) response. IOP has a significant benefit on the antigen presentation ability of vaccine preparations and the induction of T cell mediated immunity. 
